Sign in

LXEO on Nasdaq

Lexeo Therapeutics, Inc.

In its 2026 annual report the company says: “We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.”3 It is headquartered in New York, New York.1 Its shares trade on Nasdaq under the symbol LXEO.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Cardiff Oncology, Inc., ImageneBio, Inc. or Compass Therapeutics, Inc., or pick any stock.

  • TickerLXEO on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersNew York, New York1
  • Business address345 Park Avenue South, Floor 6, New York, Ny 100102
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-9252.1%Operating margin4
-9063.8%Net margin4
-$55.2MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$49.2M
  • Interest0¢$91.0K

Out of $654.0K in revenue.4 The company lost money this year.

Financial statements

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development expenses$63.8M$74.1M
General and administrative$45.5M$31.7M
Total operating expenses$109.3M$105.8M
Operating loss-$109.3M-$105.8M
Gain on long-term investment$3.4M$0
Other expense, net-$18.0K-$9.0K
Interest expense-$95.0K-$137.0K
Interest income$6.1M$7.6M
(Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net-$111.0K$23.0K
Total other income and expense$9.3M$7.4M
Loss from operations before income taxes-$100.0M-$98.3M
Income taxes$0$0
Net loss-$100.0M-$98.3M
Net unrealized gain (loss) on investments$291.0K-$103.0K
Total other comprehensive gain (loss)$291.0K-$103.0K
Comprehensive loss-$99.7M-$98.4M
Net loss per common share, basic-$1.86-$3.09
Net loss per common share, diluted-$1.86-$3.09
Weighted average number of shares outstanding used in computation of net loss per common share, basic53.6M shares31.8M shares
Weighted average number of shares outstanding used in computation of net loss per common share, diluted53.6M shares31.8M shares

Compare Lexeo Therapeutics, Inc. with another company

Corporate structure

Lexeo Therapeutics, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Lexeo Therapeutics, Inc.

  • Lexeo Therapeutics, Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Lexeo Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$100.0K8 Dec 31, 2024
Property and equipment, before depreciation$1.9M7 Dec 31, 2025$1.5M7 Dec 31, 2024+25.2%
Accumulated depreciation$741.0K7 Dec 31, 2025$474.0K7 Dec 31, 2024+56.3%
Property and equipment, net$1.1M7 Dec 31, 2025$1.0M7 Dec 31, 2024+10.8%
Finance-lease assets$1.1M7 Dec 31, 2025$1.5M7 Dec 31, 2024−21.9%
Operating-lease assets (leased space)$6.6M7 Dec 31, 2025$8.1M7 Dec 31, 2024−18.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$63.0M7 Dec 31, 2025$35.0M7 Dec 31, 2024+79.9%
Marketable securities, current$118.8M7 Dec 31, 2025$86.5M7 Dec 31, 2024+37.3%
Marketable securities, non-current$64.8M7 Dec 31, 2025$7.0M7 Dec 31, 2024+824.1%
Debt securities available for sale$183.6M7 Dec 31, 2025$93.5M7 Dec 31, 2024+96.3%
Long-term investments$7.0M8 Dec 31, 2024

Properties, in its own words

Our corporate headquarters is located at 345 Park Avenue South, 6th Floor, New York, NY 10010, where we lease a total of approximately 15,839 square feet of office and laboratory space, excluding the additional approximate 11,588 square feet that we began to lease in the first quarter of 2026, used for our research and development activities, general and administrative activities and other activities. This lease agreement began in April 2022 and expires in July 2029 with an additional five-year option to extend at the then-prevailing effective market rental rate. In March 2026, the original lease agreement was amended to include an additional approximate 11,588 square feet of leased office and laboratory space at the same address as the original headquarters lease and to be used for the same purposes. The amended lease agreement began in March 2026 with an initial term of three months, which will automatically renew for an additional three-month period(s) unless either party provides written notice to terminate the agreement.

We believe that our current facilities are sufficient to meet our current and near term needs and that suitable additional or substitute space will be available at commercially reasonable terms as and when needed.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led Lexeo Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Richard Nolan Townsend2023–now

Chief financial officer

  1. Kyle Rasbach2024–2025
  2. Louis Edward Tamayo2025–now

Chief operating officer

  1. Jose Manuel Otero2026–now
2025
Board members and other officers (16)

Timeline

  1. Sep 29, 20268-K Completed an acquisition or sale; Unregistered sale of shares28
  2. Sep 22, 20268-K Entered a material agreement; Other events29
  3. Aug 12, 20268-K Results of operations; Other events30
  4. Jun 29, 20268-K Shareholder vote31
  5. Jun 15, 20268-K Regulation FD disclosure; Other events32
  6. May 11, 20268-K Results of operations; Other events33
  7. Apr 30, 20268-K Executive or director change34
  8. Mar 30, 20268-K Results of operations; Other events35
  9. Feb 5, 20268-K Executive or director change36
  10. Jan 27, 20268-K Executive or director change37
  11. Jan 12, 20268-K Regulation FD disclosure; Other events38
  12. Nov 5, 20258-K Results of operations39
  13. Nov 2, 2023New chief executive Richard Nolan Townsend becomes CEO9

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.33) a share, on Nov 5, 2025.40

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results30
  2. May 11, 2026Reported quarterly or annual results33
  3. Mar 30, 2026Reported quarterly or annual results35
  4. Nov 5, 2025Reported quarterly or annual results39
  5. Oct 17, 2025Reported quarterly or annual results41
  6. Aug 14, 2025Reported quarterly or annual results42
  7. May 12, 2025Reported quarterly or annual results43
  8. Mar 24, 2025Reported quarterly or annual results44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

359 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 38 major events, 121 insider forms, 62 large holders, 125 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13G EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 28, 20264 EDGAR
  4. Sep 28, 20264 EDGAR
  5. Sep 28, 20264 EDGAR
  6. Sep 28, 20264 EDGAR
  7. Sep 22, 20268-K EDGAR
  8. Aug 19, 20264 EDGAR
  9. Aug 19, 20264 EDGAR
  10. Aug 19, 20264 EDGAR
  11. Aug 18, 2026144 EDGAR
  12. Aug 18, 2026144 EDGAR
  13. Aug 18, 2026144 EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Aug 14, 2026SCHEDULE 13G/A EDGAR
  16. Aug 14, 2026SCHEDULE 13G EDGAR
  17. Aug 13, 2026SCHEDULE 13G/A EDGAR
  18. Aug 12, 202610-Q EDGAR
  19. Aug 12, 20268-K EDGAR
  20. Aug 7, 2026SCHEDULE 13G EDGAR

The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 4 buys and 46 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 18, 2026Tamayo Louis EdwardChief Financial OfficerSale4,117$4.91$20.2KForm 4
Aug 18, 2026Otero Jose ManuelChief Operating OfficerSale1,304$4.96$6.5KForm 4
Aug 18, 2026Townsend Richard NolanChief Executive OfficerSale3,345$4.95$16.6KForm 4
Jul 1, 2026Bhalla Narinder PalChief Medical OfficerSale22,306$4.42$98.6KForm 4
Jul 1, 2026Tamayo Louis EdwardChief Financial OfficerSale4,641$4.49$20.8KForm 4
Jul 1, 2026Otero Jose ManuelChief Operating OfficerSale4,666$4.48$20.9KForm 4
Jul 1, 2026Townsend Richard NolanChief Executive OfficerSale25,947$4.48$116.2KForm 4
May 18, 2026Otero Jose ManuelChief Operating OfficerSale1,302$5.07$6.6KForm 4
May 18, 2026Townsend Richard NolanChief Executive OfficerSale3,342$5.06$16.9KForm 4
Apr 6, 2026Townsend Richard NolanChief Executive OfficerSale55,000$5.69$312.9KForm 4
Feb 18, 2026Otero Jose ManuelChief Operating OfficerSale3,016$6.40$19.3KForm 4
Feb 18, 2026Townsend Richard NolanChief Executive OfficerSale10,173$6.38$64.9KForm 4
Nov 18, 2025Otero Jose ManuelChief Operating OfficerSale721$9.27$6.7KForm 4
Nov 18, 2025See Tai SandiChief Development OfficerSale386$9.27$3.6KForm 4
Nov 18, 2025Townsend Richard NolanChief Executive OfficerSale1,127$9.27$10.4KForm 4
Nov 18, 2025Robertson JennyChief Legal OfficerSale549$9.27$5.1KForm 4
Nov 18, 2025Adler EricChief Medical OfficerSale615$9.27$5.7KForm 4
Oct 17, 2025Otero Jose ManuelChief Operating OfficerSale2,115$8.95$18.9KForm 4
Oct 17, 2025See Tai SandiChief Development OfficerSale3,888$8.95$34.8KForm 4
Oct 17, 2025Townsend Richard NolanChief Executive OfficerSale13,133$8.95$117.5KForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025R. Nolan Townsend46$632.7K$3.7M68
2025Jenny R. RobertsonJ.D.$459.6K$2.1M68
2025Louis Tamayo50$181.8K$1.7M68
2024Chief Executive Officer and Director$600.0K$4.4M68
2024Former Chief Legal Officer$436.5K$2.5M68

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Montanova Capital, LLC6,384,200$29.7M0.6%+5,134,200
Affinity Asset Advisors, LLC5,807,611$27.0M1.3%+757,400
BlackRock, Inc.5,739,455$26.7M0.0%+628,584
Ra Capital Management, L.P.5,000,000$23.3M0.2%No change
Frazier Life Sciences Management, L.P.4,824,725$22.5M0.5%+400,000
State Street Corp4,354,757$20.3M0.0%+786,515
Vestal Point Capital, LP4,320,000$20.1M0.5%−155,000
Paradigm Biocapital Advisors LP4,175,382$19.4M0.4%−2,008,752
Jupiter Topco LLC3,954,691$18.4M0.0%New
Orbimed Advisors LLC3,947,850$18.4M0.3%+345,400
Citadel Advisors LLC3,898,570$18.1M0.0%+63,571
Vanguard Capital Management LLC3,125,893$14.6M0.0%+118,800
Millennium Management LLC2,833,622$13.2M0.0%+1,220,842
Nantahala Capital Management, LLC2,600,000$12.1M0.4%+1,400,000
Woodline Partners LP2,500,532$11.6M0.0%−250,000
Balyasny Asset Management L.P.2,412,742$11.2M0.0%+823,157
Goldman Sachs Group Inc2,149,612$10.0M0.0%+199,727
683 Capital Management, LLC1,875,000$8.7M0.8%+675,000
Geode Capital Management, LLC1,747,959$8.1M0.0%+234,182
ADAR1 Capital Management, LLC1,565,950$7.3M0.3%+98,600
Avoro Capital Advisors LLC1,489,189$6.9M0.1%−385,811
Qube Research & Technologies Ltd1,376,222$6.4M0.0%+910,707
Dimensional Fund Advisors LP1,287,185$6.0M0.0%+183,601
Spruce Street Capital LP928,593$4.3M0.8%No change
Blackstone Inc.904,959$4.2M0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Lexeo Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLexeo Therapeutics, Inc.1
  • CIK0001907108
  • Employer ID (EIN)85-40125723
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address345 Park Avenue South, Floor 6, New York, NY 100101
  • Phone(212) 547-98791
  • Shares outstanding82,046,255 as of Aug 10, 20266
  • Public float$216.5M as of Jun 30, 20253
  • AuditorKPMG LLP, New York, NY PCAOB ID 185; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 4, 20221
  • Filings359 in all: 4 (98), 144 (42), 8-K (38), SCHEDULE 13G/A (30), 3 (21), 424B3 (15), SCHEDULE 13G (15), 10-Q (9)1
    All 35 form types

    CORRESP (9), SC 13G (9), SC 13G/A (8), UPLOAD (8), EFFECT (6), S-8 (5), DEFA14A (4), DRS/A (4), DRSLTR (4), 10-K (3), 424B5 (3), ARS (3), DEF 14A (3), FWP (3), S-3 (3), 4/A (2), S-1 (2), S-1/A (2), SEC STAFF LETTER (2), 10-Q/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), POS AM (1), S-3/A (1), S-8 POS (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.0001LXEOThe Nasdaq Global Market

From the cover page of the 10-K filed Mar 30, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Lexeo Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 30, 2026: 77 risks under these headings, as written.3

  • Risks related to our financial position and capital needs
  • We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
  • We have a limited operating history and no history of commercializing products, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability.
  • We will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Risks related to the development of our product candidates
  • Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed.
  • We are developing novel gene therapy product candidates, which makes it difficult to predict the time, cost and potential success of product candidate development.
  • Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is rigorous, complex, uncertain and subject to change, we cannot predict with certainty the geographic areas in which we could obtain regulatory approval nor the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.
  • Preclinical studies and clinical trials are expensive, time-consuming, difficult to design and implement and involve an uncertain outcome. Further, we may encounter substantial delays in completing the development of our product candidates.
  • The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for our product candidates, our business will be substantially harmed.
  • Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials.
The other 67 risks
  • Interim “top-line” and preliminary results from our clinical trials that we announce, publish or present from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Some of the diseases we initially seek to treat have low prevalence and it may be difficult to identify and enroll patients with these diseases. If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
  • We may seek Orphan Drug designation or Rare Pediatric Disease designation for some of our product candidates and we may be unsuccessful, or may be unable to maintain the benefits associated with Orphan Drug designation, including the potential for market exclusivity, for product candidates for which we obtain Orphan Drug designation.
  • Fast Track, Breakthrough Therapy, or Regenerative Medicine Advanced Therapy designation that we may receive from the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.
  • We have received Rare Pediatric Disease designation from the FDA for LX2006 for the treatment of FA and we may seek such designation for future product candidates. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.
  • Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidates.
  • We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.
  • We may not be successful in our efforts to build a pipeline of additional product candidates.
  • If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.
  • We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The third-party manufacturing facilities on which we rely, and any manufacturing facility that we may have in the future, may have limited capacity or fail to meet the applicable stringent regulatory requirements.
  • Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our product candidates or otherwise harm our business.
  • We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.
  • Any contamination or interruption in our manufacturing process, shortages of raw materials or failure of our suppliers of viruses to deliver necessary components could result in delays in our clinical development or marketing schedules.
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
  • Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates.
  • The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for our product candidates.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
  • The success of our product candidates will depend significantly on coverage and adequate reimbursement or the willingness of patients, commercial and government payors to pay for these procedures.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • Currently, we rely on our collaborations with Cornell University and The Regents of UCSD to conduct research and development for many of our pipeline programs, including conducting preclinical and IND-enabling studies for portions of our near-term future pipeline. Failure or delay of Cornell University or The Regents of UCSD to fulfill all or part of their respective obligations to us under our agreements, a breakdown in collaboration between the parties or a complete or partial loss of either of these relationships could materially harm our business.
  • We intend to continue to rely on third parties to conduct a significant portion of our existing clinical trials and potential future clinical trials for product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
  • We may seek collaborations with non-academic third parties for the development or commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
  • If we are unable to obtain or protect intellectual property rights related to any of our product candidates, we may not be able to compete effectively in our market.
  • Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.
  • We in-license key intellectual property necessary for the development of each of our current product candidates. If we fail to comply with our obligations in our current and future intellectual property licenses with third parties, resulting in the termination of such licenses, we could lose rights that are important to our business.
  • We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described above and below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.
  • Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
  • We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.
  • We may become subject to claims that we and our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information or trade secrets of third parties.
  • We may be subject to claims challenging the inventorship or ownership of our future patents and other intellectual property.
  • Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • We may have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Our current and future relationships with customers, healthcare providers, including physicians, and third- party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Even if we obtain FDA or EMA approval for any of our product candidates in the United States or European Union, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential.
  • Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • Enacted and future healthcare legislation may increase the difficulty and cost for us to progress our clinical programs and obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.
  • Changes in federal funding, layoffs, government shutdown, staff departures, lapse in government appropriations, and other policies and executive order impacting the normal operations of the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, any of which could negatively impact our business.
  • If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target diseases of our programs, even if they are approved.
  • If we obtain approval to commercialize any products outside of the United States or the European Union, a variety of risks associated with international operations could adversely affect our business.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • We are subject to a variety of privacy, data protection, and cybersecurity laws, rules, regulations, policies, industry standards and contractual obligations, and our failure to comply with them could harm our business.
  • We may be subject to various governmental export control and trade sanctions laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate these controls.
  • We are subject to U.S. and certain foreign anti-corruption laws and regulations. We could face liability and other serious consequences for violations.
  • Our future success depends on our ability to attract and retain key executives and advisors and to attract, retain and motivate qualified personnel.
  • We expect to expand our clinical development, manufacturing and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may be improperly classified and may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • The administrator of the 2023 Plan is authorized to exercise its discretion to reprice stock options and stock appreciation rights, and if a repricing occurs, there may be adverse consequences to our business.
  • The trading price of the shares of our common stock may be volatile, and purchasers of our common stock could incur substantial losses.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • We are an “emerging growth company” and a “smaller reporting company” and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies and smaller reporting companies, our common stock may be less attractive to investors.
  • Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.
  • Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
  • Unstable market and economic conditions may have serious adverse consequences on our business and financial condition.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
  • Our ability to utilize our net operating loss carryforwards and research tax credits to offset future taxable income may be subject to additional limitations.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may materially harm our business.
  • Our business and operations would suffer in the event of system failures, cyberattacks or a deficiency in our or our CMOs’, CROs’, manufacturers’, contractors’, consultants’ or collaborators’ cybersecurity.
  • We incur increased costs and demands upon management as a result of being a public company.
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. On October 12, 2023, Rocket filed a lawsuit in the U.S. District Court for the Southern District of New York against Lexeo and two former employees claiming, among other things, misappropriation of confidential information and trade secrets. The complaint alleges that while employees of Rocket, the individual defendants downloaded confidential Rocket company documents and other proprietary materials and that Lexeo used this information to advance its programs after the individuals became employed by Lexeo. The complaint seeks unspecified damages and injunctive relief. In August 2024, we asserted counterclaims against Rocket and Spacecraft Seven LLC, a wholly owned subsidiary of Rocket, for misappropriation of trade secrets, correction of inventorship of certain PKP2-ACM patents, breach of contract, and tortious interference with contract in connection with their diligence of a PKP2-ACM program at UCSD that was later licensed by Lexeo. Our counterclaims seek equitable relief, damages, attorneys' fees and costs from Rocket and Spacecraft Seven LLC. In June 2025, the litigation was resolved amicably and without admission of liability by any party, and all claims have been dismissed with prejudice.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68